We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Daiichi Selects Evotec as Partner for Medicinal Chemistry and Compound Profiling

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Daiichi Selects Evotec as Partner for Medicinal Chemistry and Compound Profiling"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Evotec AG has announced that it has signed a research collaboration agreement with Daiichi Pharmaceutical Co., Ltd. (a wholly owned subsidiary of Daiichi Sankyo Company, Limited), Tokyo, Japan, for medicinal chemistry and compound profiling.

A group of Evotec FTEs will work initially on two programmes for Daiichi to identify lead structures for further progression into clinical trials.

Daiichi will take advantage of Evotec’s expertise and full range of medicinal chemistry capabilities including compound design, parallel synthesis, computational chemistry as well as ADMET services.

In addition, Evotec will provide assay development and compound profiling skills to determine the activity and selectivity of the compounds generated.

"Evotec is an industry leader in the supply of medicinal chemistry services to the biotechnology and pharmaceutical industries," commented Dr Hirofumi Terasawa, General Manager, Medicinal Chemistry Research Laboratory of Daiichi.

"With their depth and level of scientific expertise, their track record, and their outstanding communications skills, Evotec is a trusted partner and we look forward to working with their team in developing novel compounds to treat unmet medical needs."

Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said, "We are very pleased that Daiichi has selected Evotec as their partner of choice to support them in the advancement of this new class of compounds."

"This agreement serves as another confirmation of our expertise in both, chemistry and biology for small molecule drug discovery and our commitment to supporting Japanese Pharmaceutical companies such as Daiichi."